Piper Sandler raised the firm’s price target on Veeva (VEEV) to $280 from $230 and keeps an Overweight rating on the shares. The $6B revenue target for CY30 unveiled at the 2024 analyst session hints at the strong ambitions for Veeva to further penetrate the $2+ trillion life sciences industry, Piper told investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV: